RELMADA THERAPEUTICS, INC. Payments to Acquire Short-term Investments
RELMADA THERAPEUTICS, INC. (RLMD) reported Payments to Acquire Short-term Investments of $174.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. payments to acquire short-term investments for the quarter ending 2026-06-30 was $24.75M, a 7600.20% increase year-over-year.
- RELMADA THERAPEUTICS, INC. payments to acquire short-term investments for the quarter ending 2026-03-31 was $149.52M, a 30544.10% increase year-over-year.
- RELMADA THERAPEUTICS, INC. payments to acquire short-term investments for the quarter ending 2025-12-31 was $82.79M, a 12545.88% increase year-over-year.
- RELMADA THERAPEUTICS, INC. payments to acquire short-term investments for the quarter ending 2025-09-30 was $233.93K, a 92.48% decline year-over-year.
- RELMADA THERAPEUTICS, INC. payments to acquire short-term investments for fiscal 2025 was $83.83M, a 593.97% increase from fiscal 2024.
- RELMADA THERAPEUTICS, INC. payments to acquire short-term investments for fiscal 2024 was $12.08M, a 86.65% decline from fiscal 2023.
- RELMADA THERAPEUTICS, INC. payments to acquire short-term investments for fiscal 2023 was $90.46M, a 91.28% increase from fiscal 2022.
- RELMADA THERAPEUTICS, INC. payments to acquire short-term investments for fiscal 2022 was $47.29M.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $174.27M 10-Q · filed 2026-08-06 | $257.06M derived: sum of 3 quarters · filed 2026-08-06 | $257.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $149.52M 10-Q · filed 2026-05-12 | $232.30M derived: sum of 2 quarters · filed 2026-05-12 | $232.54M derived: sum of 3 quarters · filed 2026-05-12 | $232.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $82.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $83.02M derived: sum of 2 quarters · filed 2026-03-19 | $83.34M derived: sum of 3 quarters · filed 2026-08-06 | $83.83M 10-K · filed 2026-03-19 |
| 2025-09-30 | $233.93K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $555.39K derived: sum of 2 quarters · filed 2026-08-06 | $1.04M 10-Q · filed 2025-11-13 | $1.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $321.46K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $809.38K 10-Q · filed 2026-08-06 | $1.46M derived: sum of 3 quarters · filed 2026-08-06 | $4.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $487.92K 10-Q · filed 2026-05-12 | $1.14M derived: sum of 2 quarters · filed 2026-05-12 | $4.25M derived: sum of 3 quarters · filed 2026-05-12 | $5.55M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $654.64K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $3.77M derived: sum of 2 quarters · filed 2026-03-19 | $5.07M derived: sum of 3 quarters · filed 2026-03-19 | $12.08M 10-K · filed 2026-03-19 |
| 2024-09-30 | $3.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $4.41M derived: sum of 2 quarters · filed 2025-11-13 | $11.42M 10-Q · filed 2025-11-13 | $44.74M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $8.31M 10-Q · filed 2025-08-07 | $41.62M derived: sum of 3 quarters · filed 2025-08-07 | $53.20M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $7.01M 10-Q · filed 2025-05-12 | $40.33M derived: sum of 2 quarters · filed 2025-05-12 | $51.90M derived: sum of 3 quarters · filed 2025-05-12 | $62.71M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $33.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $44.89M derived: sum of 2 quarters · filed 2025-03-27 | $55.70M derived: sum of 3 quarters · filed 2025-03-27 | $90.46M 10-K · filed 2025-03-27 |
| 2023-09-30 | $11.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $22.38M derived: sum of 2 quarters · filed 2024-11-07 | $57.15M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $10.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $45.58M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $34.77M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $47.29M 10-K · filed 2024-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |